Literature DB >> 28551695

Down syndrome, increased risk of dementia and lipid disturbances.

Anna Kłosowska1, Agnieszka Ćwiklińska2, Agnieszka Kuchta2, Agata Berlińska1, Maciej Jankowski2, Jolanta Wierzba3.   

Abstract

Down syndrome (DS) is the most common chromosomal aberration and genetically determined cause of intellectual disability. DS patients often present with some congenital defects and chronic diseases, including early onset dementia, which affects 70% of DS patients over 55 years of age and has a clinical presentation similar to Alzheimer disease (AD). The symptoms of DS originate from excessive genetic material within the "critical region" of the 21st chromosome. The "critical region" encompasses genes potentially associated with increase risk of dementia, e.g. the APP gene (amyloid beta precursor protein) which leads to excessive amyloid beta production. Post-mortem studies of DS patients' brains revealed diffuse deposition of the insoluble form of amyloid beta (Aβ), which is a characteristic feature of AD. Moreover, those changes were commonly observed in subjects > 31 years old. The pathomechanisms of AD have not been fully elucidated and scientists are still searching for new risk factors that may contribute to the development of this common illness. Recent research proved that lipid disturbance, especially disorders in the metabolism of HDL (high density lipoprotein) may play a crucial role in this pathogenic process. There are many studies examining lipid and lipoprotein concentration in the DS population, but up to now there are insufficient studies comparing these parameters with memory impairment, which may be a useful model for better understanding of the dementia pathomechanism.

Entities:  

Keywords:  Alzheimer disease ; Down syndrome ; dementia, lipids

Mesh:

Year:  2017        PMID: 28551695

Source DB:  PubMed          Journal:  Dev Period Med


  3 in total

1.  Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome.

Authors:  Aleksandra Krzesińska; Anna Kłosowska; Kornelia Sałaga-Zaleska; Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Gabriela Chyła; Jolanta Wierzba; Maciej Jankowski; Agnieszka Kuchta
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

2.  Neuroinflammatory Markers in the Serum of Prepubertal Children with Down Syndrome.

Authors:  Luigi Tarani; Valentina Carito; Giampiero Ferraguti; Carla Petrella; Antonio Greco; Massimo Ralli; Marisa Patrizia Messina; Debora Rasio; Enrica De Luca; Carolina Putotto; Paolo Versacci; Mauro Ceccanti; Marco Fiore
Journal:  J Immunol Res       Date:  2020-03-23       Impact factor: 4.818

Review 3.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.